PDCD1 and non-small cell lung carcinoma: However, this strong prognostic value of SAA could be clinically relevant because a simple blood sample makes possible to individuate a subset of patients (about two third of PD-L1 overexpressing NSCLC population) who may benefit the most from anti-PD-1 therapy (ORR 53%, mPFS 17.2 mo) compared to the remaining one-third of patients having “high” pre-treatment SAA, who contrarily reached a very poor OS (7 months) and whose ORR (7%) and mPFS (2.1 mo) potentially underlie a primary resistance to ICIs, probably including the limited cases of hyper-progression.